argenx SE (ARGNF)
USD 697.42
(0.33%)
USD 697.42
(0.33%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.54 Billion USD | 44.93% |
| 2022 | 3.13 Billion USD | 9.96% |
| 2021 | 2.85 Billion USD | 24.75% |
| 2020 | 2.28 Billion EUR | 42.31% |
| 2019 | 1.6 Billion EUR | 142.65% |
| 2018 | 661.69 Million EUR | 48.7% |
| 2017 | 444.97 Million EUR | 300.02% |
| 2016 | 111.24 Million EUR | 121.37% |
| 2015 | 50.25 Million EUR | -29.37% |
| 2014 | 71.14 Million EUR | 105.99% |
| 2013 | 34.53 Million EUR | 50.63% |
| 2012 | 22.92 Million EUR | -28.21% |
| 2011 | 31.94 Million EUR | 160.5% |
| 2010 | 12.26 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 4.79 Billion USD | 0.0% |
| 2024 Q1 | - USD | -100.0% |
| 2023 FY | 4.54 Billion USD | 44.93% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | 3.19 Billion USD | 0.0% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q4 | 4.54 Billion USD | 0.0% |
| 2022 Q4 | 3.13 Billion USD | 0.0% |
| 2022 Q2 | 3.24 Billion USD | 0.0% |
| 2022 FY | 3.13 Billion USD | 9.96% |
| 2022 Q3 | - USD | -100.0% |
| 2021 Q2 | 3.21 Billion USD | 0.0% |
| 2021 FY | 2.85 Billion USD | 24.75% |
| 2021 Q4 | 2.85 Billion USD | 0.0% |
| 2020 Q2 | 2.27 Billion EUR | 0.0% |
| 2020 FY | 2.28 Billion EUR | 42.31% |
| 2020 Q4 | 2.28 Billion EUR | 0.0% |
| 2019 FY | 1.6 Billion EUR | 142.65% |
| 2019 Q4 | 1.43 Billion EUR | 0.0% |
| 2019 Q2 | 1.14 Billion EUR | 0.0% |
| 2018 FY | 661.69 Million EUR | 48.7% |
| 2018 Q4 | 661.69 Million EUR | 0.0% |
| 2018 Q2 | 416.25 Million EUR | 0.0% |
| 2017 Q2 | 212.18 Million EUR | 0.0% |
| 2017 FY | 444.97 Million EUR | 300.02% |
| 2017 Q4 | 444.97 Million EUR | 0.0% |
| 2016 Q4 | 111.24 Million EUR | 0.0% |
| 2016 Q2 | 130.51 Million EUR | 0.0% |
| 2016 FY | 111.24 Million EUR | 121.37% |
| 2015 Q4 | 50.25 Million EUR | 0.0% |
| 2015 FY | 50.25 Million EUR | -29.37% |
| 2015 Q2 | 61.15 Million EUR | 0.0% |
| 2014 Q1 | 30.99 Million EUR | -10.26% |
| 2014 Q4 | 71.14 Million EUR | 0.0% |
| 2014 Q2 | 38 Million EUR | 22.61% |
| 2014 FY | 71.14 Million EUR | 105.99% |
| 2013 Q4 | 34.53 Million EUR | 0.0% |
| 2013 FY | 34.53 Million EUR | 50.63% |
| 2012 FY | 22.92 Million EUR | -28.21% |
| 2011 FY | 31.94 Million EUR | 160.5% |
| 2010 FY | 12.26 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -196643103.463% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -231872.399% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -42940.155% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -822630.204% |
| Rebus Holdings, Inc. | 5000.00 USD | -90849060.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -3388.543% |
| Qrons Inc. | 420.00 USD | -1081537519.048% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -589336.627% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -16155.575% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -945148.535% |
| Skye Bioscience, Inc. | 11.94 Million USD | -37942.727% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -11593.202% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -62817.005% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -5949107.638% |
| SQZ Biotechnologies Company | 107.18 Million USD | -4137.881% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -317103.666% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -6277047.792% |
| Mesoblast Limited | 667.9 Million USD | -580.11% |
| Marizyme, Inc. | 22.01 Million USD | -20533.398% |
| Genus plc | 1.02 Billion USD | -341.487% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -334309.244% |
| Pharming Group N.V. | 462.85 Million USD | -881.402% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -137009.615% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -910141.083% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -724374.96% |
| ContraFect Corporation | 20.67 Million USD | -21866.526% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1163540.788% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1188474.404% |
| IMV Inc. | 31.33 Million USD | -14396.996% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -109461.84% |
| MultiCell Technologies, Inc. | 126.22 USD | -3598841604.96% |
| ONE Bio Corp. | 70.08 Million USD | -6381.309% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -483300.146% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -3434.712% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1052091.497% |
| Q BioMed Inc. | 3.51 Million USD | -129111.664% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -12812.414% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1738460.225% |
| Biomind Labs Inc. | 73.81 Thousand USD | -6153407.904% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -917.783% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -313423.135% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -15033.984% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -165300.725% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -660634.619% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -174395.428% |
| GB Sciences, Inc. | 103.44 Thousand USD | -4391209.139% |
| Alpha Cognition Inc. | 2.45 Million USD | -185142.377% |
| HST Global, Inc. | 1526.00 USD | -297670804.325% |
| CSL Limited | 38.02 Billion USD | 88.053% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -459678.312% |
| Halberd Corporation | 10.13 Thousand USD | -44837112.516% |
| Enzolytics Inc. | 361.7 Million USD | -1155.84% |
| Agentix Corp. | 261.39 Thousand USD | -1737695.342% |
| Resverlogix Corp. | 8.11 Million USD | -55876.069% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -241792.879% |
| MetaStat, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -9422.573% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -710040.763% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -19939577.802% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -50658.513% |
| AVAX Technologies, Inc. | 7.37 Million USD | -61474.642% |
| Zenith Capital Corp. | 7410.00 USD | -61301627.395% |
| Genscript Biotech Corporation | 3.38 Billion USD | -34.139% |
| Ember Therapeutics, Inc. | 184.00 USD | -2468727073.913% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1411451.68% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1737881.512% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -489409.581% |
| Kadimastem Ltd | 2.3 Million USD | -197048.45% |
| Helix BioMedix, Inc. | 3.02 Million USD | -150059.632% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -8519.301% |
| BioStem Technologies, Inc. | 14.56 Million USD | -31097.577% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -7956003.969% |
| LadRx Corporation | 2.3 Million USD | -196723.668% |
| Cell Source, Inc. | 195.17 Thousand USD | -2327324.669% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1284470.029% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1284470.029% |
| NovAccess Global Inc. | 62.24 Thousand USD | -7297255.738% |
| Affymax, Inc. | 7.44 Million USD | -60929.934% |
| Itoco Inc. | 1.4 Million USD | -324344.6% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -4748593.77% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -4285237.736% |
| Mobile Lads Corp. | 52.00 USD | -8735496053.846% |
| CytoDyn Inc. | 11.13 Million USD | -40690.751% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -3177066.158% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -25405146.085% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1178317.572% |
| SYBLEU INC | 330.46 Thousand USD | -1374453.058% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1109380.683% |
| International Stem Cell Corporation | 5.39 Million USD | -84175.659% |
| Bioxytran, Inc. | 137.63 Thousand USD | -3300193.524% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -30179.359% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -27298.866% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -5749846.835% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -525235.819% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -60329.134% |
| Neutra Corp. | 2851.00 USD | -159328486.461% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -13917.336% |
| PureTech Health plc | 693.97 Million USD | -554.558% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -56180.608% |
| IXICO plc | 15.84 Million USD | -28570.069% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -54747.356% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -4296.324% |
| CSL Limited | 38.02 Billion USD | 88.053% |
| Cellectis S.A. | 333.99 Million USD | -1260.039% |